Colorectal Cancer

Patients aged 80 years and older with colorectal cancer (CRC) could have an improved prognosis at the completion of adjuvant chemotherapy.

Skeletal muscle proved to be significant in calculating chemotherapy toxicities in nonmetastatic colorectal cancer (CRC).

Patients with metastatic colorectal cancer (CRC) who experience colon perforation may have similar survival times to those without perforation.

Predicting clinical outcomes in patients with colorectal cancer (CRC) could be done using the novel comprehensive blood indicator PSI.

Although the incidence of colorectal cancer (CRC) decreased in individuals older than 50 years, incidence of CRC increased in male individuals younger than 50 years.

A Mendelian randomization found that a potential link between constipation and colorectal cancer, with support for constipation as a cause of colorectal cancer.

Patients with colorectal cancer (CRC) who had diagnosed metachronous metastasis had longer overall survival when the primary tumor was detected through screening.

More than 10% of fecal immunochemical test (FIT)–based colorectal cancer screening could not be processed due to unsatisfactory samples.

Critically ill older patients with colorectal cancer (CRC) had their 28-day mortality predicted using machine learning algorithms.

The implementation of a mailed stool test program increased colorectal cancer (CRC) screen-up-to-date rates compared with lower-intensity interventions, such as patient letters.

The FDA has approved fruquintinib (Fruzaqla) for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.

Caecal cancer and ascending colon cancer had slower rates of metastasis to main nodes compared with transverse colon cancer.

Postoperative circulating tumor DNA (ctDNA)–based minimal residual disease status demonstrated prognostic value for patients with stage 1 to 4 resected colorectal cancer, showing that those with positive ctDNA after surgery have significantly lower disease-free survival outcomes at 24 months vs those who were ctDNA negative.

Patients with colorectal cancer (CRC) can use C-reactive protein (CRP), lymphocyte to CRP ratio, and CRP to albumin ratio as markers for CRC prognosis.

Patients who underwent surgery for colorectal cancer had a higher risk of postoperative infection if they had high body mass index (BMI) or diabetes, among other risk factors.

The incidence of colorectal serrated lesions could be attributed to metabolic syndrome, which causes metabolic dysregulation.

The FDA has approved the CRCdx RAS Mutation Detection Kit as a companion diagnostic for panitumumab in the treatment of patients with metastatic colorectal cancer (mCRC), according to an announcement from EntroGen.

Experts in colorectal cancer (CRC) discussed the new health recommendations from the Network for Excellence in Health Innovations report and how they apply to the disparities in screening for CRC.

Significant increases in clinical staging for colorectal cancer were found when evaluating the extended timeframes beyond pre– and post–COVID-19 periods.

Patients who spoke Somali were more willing to get a screening for colorectal cancer (CRC) after a video intervention.

Successfully increasing colorectal cancer screening rates in African Americans could be achieved through the key roles of in-person interactions and community contexts.

Younger patients who had colorectal cancer (CRC) stoma had more symptom distress, were depressed and anxious, and had higher supportive care needs.

Sarcopenia or myosteatosis combined with low prediagnostic physical exercise was associated with increased mortality from colorectal cancer (CRC).

The integration of novel mRNA biomarkers into the ColoAlert screening test resulted in high sensitivity and specificity for detecting colorectal cancer (CRC).

Although nofazinlimab was well tolerated and showed antitumor activity in many tumor types, no response was found when combined with regorafenib to treat metastatic colorectal cancer (mCRC).